PQ Bypass Receives FDA “Breakthrough Device Designation” for the World’s First Fully Percutaneous Femoral-Popliteal Bypass Device

September 2, 2020

PQ Bypass Inc, announced today that they received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Detour System. The Detour System is the world’s first fully-percutaneous femoral-popliteal bypass device intended to treat extremely long, complex blockages in the superficial femoral artery (SFA).

PQ Bypass advises physician access to this device can now be expedited as a result of this designation by the FDA Breakthrough Device Program, which is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. Under the program, the FDA will provide PQ Bypass with priority review and interactive communication regarding device development and clinical trial protocols, during the premarket review process.

“As this is a first-of-its-kind device, we are pleased to have the FDA recognize the novelty and potential of our therapeutic approach in treating severe SFA,” said Heather Simonsen, General Manager at PQ Bypass. “We appreciate their collaborative review of our Breakthrough Device designation request and look forward to a continued productive relationship as we continue towards PMA submission.”

The Detour System is designed to treat patients who are unable to carry out activities of daily living and are unable to enjoy the liberties of free mobility as a result of their advanced symptomology, severe lesion morphology, and multiple co-morbidities. Once PAD progresses to debilitating claudication or tissue loss, revascularization becomes imperative to mitigate the ongoing deterioration and to prevent amputation. Left untreated, these patients are at greater risk for further functional deterioration, major adverse limb events, and mortality.

“This designation is a major milestone for PQ Bypass, and we expect this technology to change the paradigm for complex SFA treatment in the way EVAR and TAVR changed the paradigm for aortic repair,” said Rich Ferrari, Chairman and CEO of PQ Bypass. “We are nearing enrollment completion in our DETOUR2 and TORUS2 IDE studies, and had new positive data on our technology published in the Journal of Vascular Surgery, making 2020 a momentous year for the company.

This is an exciting time for all of us at PQ, with this important designation a credit to such a talented group. We are honored and proud to be part of this important journey to develop a first-line therapy in the treatment of advanced PAD.”

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.